AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06617832
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo pill (100 mg) looking like the active drug
Trial: NCT06682169
Drug: Rovadicitinib
RxNorm normalized name: Rovadicitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovadicitinib is an inhibitor of Janus associated kinases (JAK) family and Rho associated kinases (ROCK). It can inhibit the sustained abnormal activation of the Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway and also inhibit Rho associated kinase 2 (ROCK2). The JAK 1-JAK 2 signaling pathway is a key step in causing inflammation and tissue damage in acute and chronic graft-versus-host disease.
Trial: NCT06682169
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate is an organic compound, mainly used as an anti folate anti-tumor drug. It inhibits the synthesis of tumor cells by inhibiting dihydrofolate reductase, thereby inhibiting the growth and reproduction of tumor cells.
Trial: NCT06693960
Drug: Drug cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drug cocktail consisting of caffeine (100 mg), dextromethorphan (30 mg), losartan (25 mg), midazolam syrup (2 mg), and omeprazole (20 mg).
Trial: NCT06710431
Drug: AFA-281
RxNorm normalized name: ADAPTER,ASPIRA/FLUSH,LUER URESIL AFA-LL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFA-281
Trial: NCT05442190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment is identical to SGX302 ointment (color matched) but it does not contain hypericin.
Trial: NCT05502341
Drug: BIC/LEN FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food
Trial: NCT05502341
Drug: Stable Baseline Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).~* Nucleos(t)ide Reverse Transcriptase Inhibitors:~  * Abacavir~ * Emtricitabine~ * Lamivudine~ * Tenofovir alafenamide~ * Tenofovir disoproxil fumarate~ * Zidovudine~* Non-Nucleosite Reverse Transcriptase Inhibitors:~  * Delavirdine~ * Efavirenz~ * Nevirapine~ * Rilpivirine~ * Doravirine~* Integrase Inhibitors:~  * Bictegravir~ * Cabotegravir~ * Dolutegravir~ * Elvitegravir~ * Raltegravir~* Protease Inhibitors:~  * Atazanavir~ * Darunavir~ * Fosamprenavir~ * Indinavir~ * Lopinavir~ * Nelfinavir~ * Saquinavir~ * Tipranavir~* Chemokine Co-receptor 5 (CCR5) Antagonist:~  * Maraviroc~* Fusion Inhibitors:~  * Enfuvirtide~* gp120 Attachment Inhibitor:~  * Fostemsavir~* Anti-CD4 Monoclonal Antibodies:~  * Ibalizumab-uiyk
Trial: NCT05957367
Drug: DCC-3116
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet Formulation
Trial: NCT06199037
Drug: SHR-1707 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 placebo injection
Trial: NCT04797000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)
Trial: NCT05296681
Drug: NBT-NM108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive irinotecan-based chemotherapy per standard of care.
Trial: NCT06431373
Drug: Placebo PO QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PO QD
Trial: NCT04713657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients who are randomized to receive placebo, the first dose will be given in the Pediatric Translational Research Center (PCTRC) and will be based on the patients weight. Parents will administer placebo 4 doses per day. Treatment with placebo will begin at 1 month of age and continue until surgical repair, which happens usually at 3 - 9 months of age.
Trial: NCT06391905
Drug: PCSK9 inhibitor in combination with standard advanced first-line regimen group
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorouracil and platinum as the base chemotherapy regimen, with or without targeted therapy, was administered subcutaneously at a fixed dose of 150 mg of PCSK9 inhibitor every two weeks starting on day 1 of patient enrollment
Trial: NCT05817526
Drug: BMAC/ collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow aspirate concentrate loaded on collagen in the peri-implant defect
Trial: NCT06143553
Drug: Capecitabine Tablets
RxNorm normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects are given 1000-1250mg/m2 of Capecitabine Tablets on days 1 to 14 of the 21-day cycle ,and twice a day (once in the morning and once in the evening; Total daily dose 2000-2500mg/m2).
Trial: NCT04912011
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
Trial: NCT04946461
Drug: Dexamfetamine Sulfate 5 Mg Oral Tablet
RxNorm normalized name: Dexamfetamine sulfate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage is set based on the recommendation of the practitioner. Dexamphetamine is administered twice a day, with an interval of 4 hours.
Trial: NCT05712876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT05128929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet placebo (inactive ingredients) two times a day.
Trial: NCT05255653
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.
Trial: NCT06492005
Drug: 9MW2821
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive intravenous (IV) infusion of 9MW2821 as per protocol
Trial: NCT05014490
Drug: Exib 120 mg etoricoxib film-coated tablets
RxNorm normalized name: etoricoxib 120 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, COX-2 highly selective, non-steroidal anti-inflammatory generic drug
Trial: NCT05014490
Drug: Arcoxia® 120 mg etoricoxib film-coated tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, COX-2 highly selective, non-steroidal anti-inflammatory innovative drug
Trial: NCT05559554
Drug: AK104 (after the change)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
Trial: NCT05219500
Drug: FPI-2265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225
Trial: NCT05693844
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously at a total dose of 15-30mg/kg on day -3 and day -2
Trial: NCT05672199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection
Trial: NCT06648681
Drug: Control (placebo) group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive an oral placebo tablet daily between 2000h and 0000h for the first 7 days following extubating/initiation criteria is met or until their hospital discharge, whichever occurs first. The initiation criteria and the procedure if sleep is not initiated within 1 hour is the same as the intervention arm .
Trial: NCT05387954
Drug: Oral Anticoagulant, Direct-Acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (5mg twice a day) OR Dabigatran (150 mg twice a day) OR Rivaroxaban (20 mg once a day)
Trial: NCT05494320
Drug: Folfox Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folfox: It includes the drugs leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin.
Trial: NCT05387954
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to this arm will receive antiplatelet therapy throughout the study : aspirin 75 mg/d + clopidogrel 75 mg/d) for 3 months, then single antiplatelet therapy by aspirin or clopidogrel
Trial: NCT04240054
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15
Trial: NCT04811573
Drug: EU-sourced Otezla®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product
Trial: NCT04811573
Drug: US-sourced Otezla®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product 1
Trial: NCT04811573
Drug: Japan-sourced Otezla®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product 2
Trial: NCT06217302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive tablets identical to sotagliflozin tablets
Trial: NCT05569811
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 14 or 21 days) followed by weekly paclitaxel 80mg/m2 during 12 weeks
Trial: NCT05718817
Drug: XEN1101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN1101 capsules
Trial: NCT05718544
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
Trial: NCT05320302
Drug: [11C]-Lu AF88370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET ligand in a single intravenous bolus injection
Trial: NCT05633615
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06184399
Drug: Placebo IVM ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for ivermectin ODT
Trial: NCT06460038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug
Trial: NCT04581759
Drug: foundational treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs
Trial: NCT05056844
Drug: Iodinated Contrast Agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given iodine-based contrast agent IV
Trial: NCT06798896
Drug: SPN-817
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-817 starting at 0.25 mg bid up to 4.00 mg bid
Trial: NCT06798896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, bid
Trial: NCT06027086
Drug: DRP-104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive treatment twice a week of each cycle. DRP-104 (145 mg,125mg, 105mg, 85mg or 65mg) will be administered subcutaneous injection twice a week of each 28 day cycle.~After the first cycle of treatment the study drug may be shipped to the patient's home for future cycles of administration if patients or caregiver can demonstrate at least two observed independent injections of DRP-104 prior to home administration.
Trial: NCT05834413
Drug: chemotherapy plus TCM 1&ICIs plusTCM2 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang and Xu Ling. Package of granules is made into two types with functions such as tonifying the stomach and nourishing the blood recipe, benefiting Qi Yin and detoxification and resolving masses recipe. The herbal treatment is adapted to the syndromes.~Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.
Trial: NCT05834413
Drug: chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.
Trial: NCT04710056
Drug: REGN4461
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05484375
Drug: Capecitabine plus toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine tablet: 650mg/m2, orally, twice a day, d1-d21, every 3 weeks Toripalimab: 240mg, intravenous drip, d1, every 3 weeks
Trial: NCT06403670
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group RP received remifentanil 0.1 mcg/kg intravenously for 30 seconds, then remifentanil infusion was started at 0.01-0.1 mcg/kg/min. After waiting 2 minutes to develop a sufficient sedation level, 1 mg/kg of propofol was given.
Trial: NCT05627648
Drug: KP-100LI
RxNorm normalized name: Draxxin KP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracordal injection, 20 mcg once per week, 3 weeks
Trial: NCT05627648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracordal injection, once per week, 3 weeks
Trial: NCT04316546
Drug: MK-7075 (miransertib)
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7075 (miransertib) is a small molecule developed by ArQule Inc., a wholly owned subsidiary of Merck Sharp \&amp; Dohme (Merck), that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a Phase 2 trial investigating the efficacy of miransertib as a treatment for adult and pediatric patients with Proteus syndrome.
Trial: NCT05399459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet
Trial: NCT04402515
Drug: ICS
RxNorm normalized name: ICSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled cortocosteroids
Trial: NCT05012761
Drug: SR419 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single and multiple doses of SR419 orally
Trial: NCT05012761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single and multiple doses of placebo orally
Trial: NCT06528028
Drug: CAZ/AVI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous infusion is used
Trial: NCT06528028
Drug: CAZ/AVI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2h-infusion is used
Trial: NCT05755737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo identical in appearance.
Trial: NCT05472324
Drug: TQC2731 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.
Trial: NCT05472324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug is a placebo Comparator.
Trial: NCT06271421
Drug: chemotherapy according to Stupp protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide is used during radiotherapy: 75 mg/m2 of body surface area per day for 7 days a week. After the completion of radiotherapy, temozolomide is used as adjuvant therapy - 6 cycles of 150-200 mg/m2 of body surface area for 5 days every 28 days.
Trial: NCT05534087
Drug: FOLFOX or CAPOX adjuvant chemotherapy
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. FOLFOX regimen: 6 cycles every 2 weeks~   * Oxaliplatin 85mg/m2 IV infusion over 120 min D1~  * Leucovorin 400mg/m2 IV infusion over 120 min (concurrently with oxaliplatin)~  * 5-fluorouracil 400mg/m2 IV bolus D1~  * 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2 or~2. CAPOX regimen: 4 cycles every 3 weeks~   * Oxaliplatin 130mg/m2 IV infusion over 120 min D1~  * Capecitabine 1,000mg/m2 PO bid D1-14
Trial: NCT06508944
Drug: vaginal 17 beta-estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Femiest® Haupt Pharma Munster GMBH, Muenster, Germany~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks.
Trial: NCT06508944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Placebo is produced by Chulalongkorn University Drug and Health Products Innovation \& Promotion Center.~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks.
Trial: NCT06403436
Drug: TT125-802
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TT125-802 administered orally
Trial: NCT05320367
Drug: Cannabis, placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible participant will be randomize 1:1:1:1:1 to receive placebo, CBD (5mg, 20mg, 50mg and 100mg). Only one research product will be inhaled for each visit. The sequence will depend on the assigned randomization group.
Trial: NCT05942027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo match Coenzyme Q10 capsules once per day .
Trial: NCT05500599
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Formulation of Fentanyl Citrate and Midazolam Administered Orally for Premedication
Trial: NCT06080048
Drug: SOR102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOR102 capsules
Trial: NCT06080048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules
Trial: NCT04910256
Drug: Huatuo Zaizao Pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients take 8g of HuaTuo Zaizao pill three times a day. Treatment lasts for 12 weeks.
Trial: NCT06287918
Drug: 3HP-2827
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3HP-2827 will be administered orally once daily in 28-day cycles.
Trial: NCT03905109
Drug: ABX464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 is a new anti-inflammatory drug. In the treatment arm, patients will receive dose A or Dose B of ABX464 orally once daily for 52 weeks.
Trial: NCT03905109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the placebo group, patients will receive dose A or B ABX464-matching-placebo orally once daily for 52 weeks.
Trial: NCT06085482
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06085482
Drug: [14C]-LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT05642182
Drug: SFA002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug formula without excipient
Trial: NCT05642182
Drug: SFA002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug SFA002 with excipient (Propionate)
Trial: NCT06178679
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution
Trial: NCT04784104
Drug: Adrenaline amp. 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
Trial: NCT00378235
Drug: IL13-PE38QQR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00631501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00631501
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05005520
Drug: DTRI-031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug
Trial: NCT05005520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to DTRI-031
Trial: NCT06274528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg; capsule; QD; 6 month duration
Trial: NCT06175702
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 on days 1 to 28 of maintenance
Trial: NCT06175702
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 on day 1 of consolidation with 24h infusion; and 20 mg/m2 on days 1, 8, 15 and 22 of maintenance
Trial: NCT06175702
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg on days -6 and -5 before alloSCT
Trial: NCT04768673
Drug: CKD-393 formulation I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single, oral administration of 2 tablets under fed condition
Trial: NCT04768673
Drug: CKD-393 formulation II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single, oral administration of 2 tablets under fed condition